Analysis of Meloxicam in accordance with the United States Pharmacopoeia (Assay)

Significance of the Topic

Meloxicam is a widely used non-steroidal anti-inflammatory drug, and reliable quantitative analysis is essential for ensuring drug quality and safety in pharmaceutical production and quality control laboratories. The assay outlined by the United States Pharmacopoeia sets regulatory standards that must be met for product release.

Objectives and Study Overview

This application note demonstrates a reversed-phase liquid chromatography method using a Shim-pack GIST C18 column to quantify meloxicam and its related impurity in accordance with the USP assay. The study evaluates system suitability criteria and the performance of a standard solution under isocratic conditions.

Methodology and Instrumentation

An overview of the analytical protocol:

• Liquid chromatograph: Shimadzu Nexera XR
• Column: Shim-pack GIST C18 (150 mm × 4.6 mm I.D., 5 µm; USP L1)
• Mobile phase: Methanol/solution A (buffer) = 21/29 (v/v)
• Flow rate: 1.0 mL/min
• Column temperature: 45 °C
• Injection volume: 10 µL
• Detection: Photodiode array at 360 nm

Key Results and Discussion

The chromatograms for the system suitability solution and the USP standard solution show clear baseline separation of meloxicam and its related compound A, with retention times reliably reproduced across injections. Peak shapes are symmetric, and resolution exceeds USP requirements, confirming method robustness and specificity for both assay and impurity evaluation.

Benefits and Practical Applications

This streamlined isocratic method offers:

• Fast analysis cycle under 10 minutes
• High reproducibility and compliance with USP assay criteria
• Minimal solvent usage and cost-effective operation
• Easy transfer to quality control settings in pharmaceutical manufacturing

Future Trends and Opportunities

Emerging directions include adaptation to ultra-high-performance liquid chromatography for further speed gains, integration with mass spectrometry for enhanced impurity profiling, exploration of greener mobile phases, and automation for real-time monitoring in continuous production environments.

Conclusion

The described LC method using a Shim-pack GIST C18 column on the Nexera XR system effectively meets USP requirements for meloxicam assay, delivering rapid, robust, and precise quantification suitable for routine pharmaceutical quality control.

References

Application News L550, Shimadzu Corporation, First Edition December 2021; ERAS-1000-0148.